clinical trial · NCT07773883
An Open-Label Study to Assess the Long-Term Safety of Solriamfetol in Children and Adolescents With ADHD
ADHDSolriamfetol
brief summary
This study is a Phase 3, multi-center, open-label trial to evaluate the long-term safety of solriamfetol in children and adolescents with ADHD.
started
Aug 6, 2026
primary completion
Dec 1, 2027
completion
Dec 1, 2027
last updated
Aug 19, 2026
detailed description
Eligible subjects are children and adolescents with ADHD who have completed either Study SOL-ADHD-302 (FOCUS-2) or Study SOL-ADHD-304 (FOCUS-3). Subjects will be assigned to age-based cohorts and will receive solriamfetol once daily for up to 52 weeks.
official title
An Open-Label Study to Assess the Long-Term Safety of Solriamfetol in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol